Doperon
Generic Name
Domperidone 10 mg tablet
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| doperon 10 mg tablet | ৳ 2.00 | ৳ 20.00 |
Description
Overview of the medicine
Domperidone is an antiemetic and prokinetic agent used to treat nausea, vomiting, and certain gastrointestinal motility disorders like functional dyspepsia and gastroesophageal reflux disease (GERD). It works by blocking dopamine receptors in the brain's chemoreceptor trigger zone and the gastrointestinal tract.
Uses & Indications
Dosage
Adults
10 mg, 3-4 times daily, 15-30 minutes before meals and at bedtime if necessary. Maximum daily dose is 30 mg.
Elderly
Similar to adults, but caution is advised due to potential increased risk of cardiac adverse events. Lower doses and shorter treatment durations may be considered. Maximum daily dose is 30 mg.
Renal_impairment
In severe renal impairment (creatinine clearance < 30 ml/min), the frequency of dosing should be reduced to 1-2 times daily depending on the severity of impairment, after initial dose adjustment.
How to Take
Oral. Take 15-30 minutes before meals for optimal absorption and effect. Do not chew or crush the tablet; swallow whole with water.
Mechanism of Action
Domperidone acts as a peripheral dopamine D2 receptor antagonist, primarily in the chemoreceptor trigger zone (CTZ) and the gastrointestinal tract. By blocking D2 receptors in the CTZ, it prevents nausea and vomiting. In the gastrointestinal tract, it enhances gastric and duodenal peristalsis, increases lower esophageal sphincter pressure, and accelerates gastric emptying, thus exerting its prokinetic effects.
Pharmacokinetics
Onset
30-60 minutes
Excretion
Approximately 66% excreted via feces (mainly as metabolites) and 33% via urine (about 10% as unchanged drug, rest as metabolites).
Half life
Approximately 7-9 hours; prolonged in severe renal impairment.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentration usually reached within 30-60 minutes. Bioavailability is low (15-20%) due to extensive first-pass metabolism in the liver.
Metabolism
Extensively metabolized in the liver primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2E1.
Side Effects
Contraindications
- •Known hypersensitivity to Domperidone or any component of the formulation.
- •Patients with prolonged cardiac conduction intervals (especially QTc), significant electrolyte disturbances, or underlying cardiac diseases (e.g., congestive heart failure).
- •Moderate to severe hepatic impairment.
- •Prolactin-releasing pituitary tumor (prolactinoma).
- •Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin, fluconazole, amiodarone, diltiazem, verapamil).
- •Gastrointestinal hemorrhage, mechanical obstruction, or perforation where stimulation of gastric motility could be harmful.
Drug Interactions
Dopamine agonists (e.g., bromocriptine, cabergoline)
Domperidone may antagonize the effects of dopamine agonists, potentially reducing their efficacy.
Antacids and antisecretory agents (e.g., proton pump inhibitors, H2-blockers)
May reduce the oral bioavailability of domperidone. Domperidone should be taken before meals and antacids/antisecretory agents after meals for optimal separation.
QTc-prolonging drugs (e.g., certain antiarrhythmics, antipsychotics, antidepressants, antibiotics)
Increased risk of QTc prolongation. Concomitant use should be avoided or used with extreme caution.
Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin, fluconazole, amiodarone, diltiazem, verapamil)
Concomitant use is contraindicated due to significantly increased plasma levels of domperidone and an increased risk of QTc prolongation and other serious cardiac events.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include drowsiness, disorientation, extrapyramidal reactions (especially in children), and QTc prolongation. Management involves symptomatic and supportive treatment, including gastric lavage and activated charcoal. ECG monitoring should be performed, and antiarrhythmic therapy may be required if QTc prolongation or arrhythmias occur.
Pregnancy & Lactation
Pregnancy: Category C. Use only if clearly needed and the potential benefits outweigh the potential risks to the fetus. Lactation: Domperidone is excreted in breast milk in small amounts. While the amount ingested by the infant is generally low, potential cardiac effects should be considered. Breastfeeding should be weighed against the potential risks to the infant, especially for infants with risk factors for QTc prolongation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months
Availability
Pharmacies, Hospitals
Approval Status
Approved by DGDA (Bangladesh)
Patent Status
Generic drug, patents expired
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
